Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers

Inclusion Criteria

• Patients with histologically confirmed peritoneal surface malignancies, including malignant peritoneal mesothelioma and peritoneal carcinomatosis (PC) from presumed appendiceal and colorectal primary tumors; most patients will have received extensive prior treatments, due to the recurrent nature of PC; prior therapies involve previous CRS, local and systemic chemotherapy, and their different numbers; none of these prior treatments disqualifies the patient from receiving the protocol-mandated experimental treatment
• Patients must be deemed able to undergo optimal cytoreductive surgery (CRS) defined as cytoreduction (CC)-score of 0 or 1 based on imaging * Cytoreduction is defined as the burden of residual disease nodules left at the end of surgery (CC-0: no visible disease; CC-1: residual tumor nodules =< 2.5 mm in size; CC-2: residual tumor nodules 2.5 mm-2.5 cm in size; CC-3: residual tumor nodules > 2.5 cm in size)
• Patients may be enrolled in the study regardless of prior chemotherapy regimens
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
• Patients must be able to understand and be willing to sign a written informed consent document
• Able to swallow pills
• Platelet >= 75,000/uL
• Hemoglobin >= 9.0 g/dL
• Hematocrit >= 27.0%
• Absolute neutrophil count (ANC) >= 1500/uL
• White blood cell (WBC) > 2000/mm^3
• Creatinine < 1.5 x institutional upper limit of normal (ULN), OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels greater than 1.5 x ULN
• Total bilirubin =< 1.5 x ULN
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN

Exclusion Criteria

• Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
• Patients with active autoimmune disease or history of transplantation; patients with indolent or chronic autoimmune disease not requiring steroid treatment are considered eligible
• Patients who are pregnant or nursing
• Patients experiencing a cardiac events (acute coronary syndrome, myocardial infarction, or ischemia) within the 3 months prior to accrual
• Patients with a New York Heart Association classification of III or IV
• Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)